60.19
0.53 (0.89%)
| Previous Close | 59.66 |
| Open | 59.55 |
| Volume | 868,728 |
| Avg. Volume (3M) | 2,657,339 |
| Market Cap | 11,563,361,280 |
| Price / Earnings (TTM) | 22.38 |
| Price / Earnings (Forward) | 11.04 |
| Price / Sales | 3.67 |
| Price / Book | 1.83 |
| 52 Weeks Range | |
| Earnings Date | 19 Feb 2026 |
| Profit Margin | 17.76% |
| Operating Margin (TTM) | 30.05% |
| Diluted EPS (TTM) | 2.70 |
| Quarterly Revenue Growth (YOY) | 14.80% |
| Quarterly Earnings Growth (YOY) | 109.40% |
| Total Debt/Equity (MRQ) | 10.39% |
| Current Ratio (MRQ) | 5.52 |
| Operating Cash Flow (TTM) | 700.26 M |
| Levered Free Cash Flow (TTM) | 411.56 M |
| Return on Assets (TTM) | 6.38% |
| Return on Equity (TTM) | 9.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BioMarin Pharmaceutical Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.77% |
| % Held by Institutions | 98.91% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 100.00 (Truist Securities, 66.14%) | Buy |
| Median | 84.00 (39.56%) | |
| Low | 60.00 (HC Wainwright & Co., -0.32%) | Hold |
| 60.00 (Leerink Partners, -0.32%) | Hold | |
| Average | 80.40 (33.58%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 57.83 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 06 Feb 2026 | 84.00 (39.56%) | Buy | 58.13 |
| Canaccord Genuity | 20 Jan 2026 | 98.00 (62.82%) | Buy | 56.31 |
| Truist Securities | 23 Dec 2025 | 100.00 (66.14%) | Buy | 61.14 |
| HC Wainwright & Co. | 22 Dec 2025 | 60.00 (-0.32%) | Hold | 59.28 |
| Leerink Partners | 03 Dec 2025 | 60.00 (-0.32%) | Hold | 54.31 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Jan 2026 | Announcement | BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility |
| 26 Jan 2026 | Announcement | BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility |
| 12 Jan 2026 | Announcement | BioMarin Appoints Arpit Davé Chief Digital and Information Officer |
| 08 Jan 2026 | Announcement | BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA |
| 08 Jan 2026 | Announcement | Veeva and BioMarin Form Long-Term Strategic Partnership |
| 19 Dec 2025 | Announcement | BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |